A phase I study of dovitinib (TKI258) in Japanese patients with advanced solid tumors

被引：0
|
作者：
Takiuchi, Hiroya
Gotoh, Masahiro
Yoshida, Motoki
Kii, Takayuki
Yamashita, Keishi
Sunakawa, Yu
Kaneta, Toshikado
Robson, Matthew
Kakizume, Tomoyuki
Sasaki, Yasutsuna
机构：
[1] Osaka Med Coll, Osaka, Japan
[2] Osaka Med Coll Hosp, Osaka, Japan
[3] Saitama Med Univ, Int Med Ctr, Saitama, Japan
[4] Novartis Pharma KK, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3088
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase I study of olaratumab in Japanese patients with advanced solid tumors
    Doi, Toshihiko
    Ma, Yan
    Dontabhaktuni, Aruna
    Nippgen, Cornelia
    Nippgen, Johannes
    Ohtsu, Atsushi
    CANCER SCIENCE, 2014, 105 (07) : 862 - 869
  • [32] A phase I study of resminostat in Japanese patients with advanced solid tumors
    Kitazono, Satoru
    Fujiwara, Yutaka
    Nakamichi, Shinji
    Mizugaki, Hidenori
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Yamada, Yasuhide
    Inukai, Eri
    Nakamura, Osamu
    Tamura, Tomohide
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (06) : 1155 - 1161
  • [33] GOLD study: An international Phase III study of TKI258/Dovitinib versus Sorafenib in patients with metastatic renal cell cancer (mRCC) as third line therapy
    Gruenwald, V
    Kube, U.
    Eichelberg, C.
    Zuern, C.
    Gschwend, J.
    ONKOLOGIE, 2012, 35 : 202 - 203
  • [34] A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258)
    Infante, Jeffrey R.
    Ramanathan, Ramesh K.
    George, Daniel
    Tan, Eugene
    Quinlan, Michelle
    Liu, Angela
    Scott, Jeffrey W.
    Sharma, Sunil
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 729 - 737
  • [35] A randomized, crossover phase 1 study to assess the effects of formulation (capsule vs tablet) and meal consumption on the bioavailability of dovitinib (TKI258)
    Jeffrey R. Infante
    Ramesh K. Ramanathan
    Daniel George
    Eugene Tan
    Michelle Quinlan
    Angela Liu
    Jeffrey W. Scott
    Sunil Sharma
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 729 - 737
  • [36] In VitroEffect of Dovitinib (TKI258), a Multi-Target Angiokinase Inhibitor on Aggressive Meningioma Cells
    Das, Arabinda
    Martinez Santos, Jaime L.
    Alshareef, Mohammed
    Porto, Guilherme Bastos Ferreira
    Infinger, Libby Kosnik
    Vandergrift, William A., III
    Lindhorst, Scott M.
    Varma, Abhay K.
    Patel, Sunil J.
    Cachia, David
    CANCER INVESTIGATION, 2020, 38 (06) : 349 - 355
  • [37] Activating FGFR2 kinase domain mutations provide resistance to dovitinib (TKI258)
    Byron, Sara A.
    Chen, Huaibin
    Mohammadi, Moosa
    Pollock, Pamela M.
    CANCER RESEARCH, 2011, 71
  • [38] Dovitinib (TKI258): Exploration of pharmacokinetics and pharmacodynamics (PK/PD) for dose and regimen consideration.
    Garonzik, Samira Merali
    Nedelman, Jerry
    Tan, Eugene
    Chiparus, Ovidiu
    Dugan, Margaret Han
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
    Kang, Chan Woo
    Jang, Kang Won
    Sohn, Jinyoung
    Kim, Sung-Moo
    Pyo, Kyoung-Ho
    Kim, Hwan
    Yun, Mi Ran
    Kang, Han Na
    Kim, Hye Ryun
    Lim, Sun Min
    Moon, Yong Wha
    Paik, Soonmyung
    Kim, Dae Joon
    Kim, Joo Hang
    Cho, Byoung Chul
    MOLECULAR CANCER THERAPEUTICS, 2015, 14 (10) : 2238 - 2248
  • [40] A multicenter, open-label phase II trial of dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated or wild-type FGFR3.
    Milowsky, M. I.
    Carlson, G. L.
    Shi, M. M.
    Urbanowitz, G.
    Zhang, Y.
    Sternberg, C. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345